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Background: It has been postulated that inflammation plays a key role in developing early recurrence of atrial fibrillation (ERAF) following 
radiofrequency catheter ablation (RFCA) for AF. ERAF increases hospital stay, need for anti-arrhythmic medications and cardioversion, and the risk of 
future AF development. Short term use of steroids to reduce ERAF in post RFCA has not been previously reported.
Methods: This was a retrospective cohort study of consecutive patients undergoing RFCA for AF at a single-institution from October 2005 through 
July 2009. Patients receiving intravenous dexamethasone at any time during their hospitalization constituted the treatment group. Controls 
received no intravenous corticosteroids any time following RFCA for AF. All patients had continuous electrocardiographic monitoring throughout their 
hospitalization. Multiple logistic regression analysis was used to determine the impact of intravenous corticosteroids on ERAF (defined as any AF> 10 
minutes during hospitalization).
Results: A total of 68 patients (mean±SD age: 55±10 years; 75% male; 56% paroxysmal atrial fibrillation; 12% heart failure; mean±SD left atrial 
size: 4.07±0.68 cm) undergoing RFCA for AF were included in the analysis. The overall ERAF rate irrespective of intravenous corticosteroid use was 
23.5%. The administration of intravenous corticosteroids (n=37; mean±SD dose in dexamethasone equivalents: 11.9±4.6 mg/day; range 4-16 mg/
day) was associated with an 82% reduction in patients’ odds of ERAF (adjusted odds ratio; 0.18, 95%CI 0.04 to 0.78) compared with those who 
did not receive corticosteroids (n=31). A dose-response effect was also observed, with a 17% reduction in ERAF odds for each dexamethasone mg-
equivalent administered (adjusted OR; 0.83, 95%CI 0.73 to 0.96).
Conclusions: The use of intravenous dexamethasone was associated with a dose-dependent reduction in the odds of developing ERAF after RFCA 
for AF.
